ClinicalTrials.gg
CompletedNCT07805837Updated Sep 4, 2026

Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults

A Phase 4 interventional study of Standard-Dose Influenza Vaccine and MF59-Adjuvanted Influenza Vaccine in Influenza, Influenza Vaccines and Microbiome, sponsored by Korea University Guro Hospital. Completed at 1 site in South Korea. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Korea University Guro Hospital · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2025, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies testing MF59 in Influenza, Human — 3 open to participants now, 3 under way, 1 of them phase 3. MF59 · Influenza, Human.

Enrollment
20th of 22
121 · median 549
Started
2025
with 2 others
Phase 4
3 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
2 of 22
Korea University Guro Hospital

Among the 22 studies testing MF59 in Influenza, Human, this one is the 20th largest by enrollment, is one of 3 that started in 2025, is one of 3 in phase 4, and was the 21st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 22 studies testing MF59 in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MF59

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing MF59 in Influenza, Human, or all of them as a file.
02

Study summary

This prospective, randomized, open-label clinical study aims to evaluate the immunogenicity and underlying immune mechanisms of different influenza vaccine formulations in adults aged ≥65 years. Additionally, the study investigates the role of the gut microbiome in modulating vaccine-induced immune responses and durability.

Read the detailed description

Despite high influenza vaccination coverage among older adults in Korea, vaccine effectiveness remains suboptimal, even during well-matched seasons. Immunosenescence and microbiome dysbiosis are believed to contribute to reduced vaccine responsiveness.

This study will:

  • Compare immune responses induced by standard-dose, MF59-adjuvanted, and high-dose influenza vaccines
  • Characterize cellular and humoral immune mechanisms
  • Analyze gut microbiome composition and function using metagenomic approaches
  • Identify microbiome-derived biomarkers associated with vaccine responsiveness and durability
03

Conditions studied

  • Influenza
  • Influenza Vaccines
  • Microbiome
  • Immune Response

Browse trials for

Keywords

  • Influenza, Influenza vaccines, Microbiome, Immune mechanism
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥65 years
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Influenza vaccination within the past 6 months
  • Laboratory-confirmed influenza infection within the past 6 months
  • status
  • Uncontrolled chronic medical conditions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    Standard-Dose Influenza Vaccine

    Intervention: Standard-dose quadrivalent influenza vaccine (Vaxigrip®) Dose: 0.5 mL intramuscular injection, single dose

    Biological: Standard-Dose Influenza Vaccine

  • Active comparator
    MF59-Adjuvanted Influenza Vaccine

    Intervention: MF59-adjuvanted vaccine (FLUAD®) Dose: 0.5 mL intramuscular injection, single dose

    Biological: MF59-Adjuvanted Influenza Vaccine

  • Active comparator
    High-Dose Influenza Vaccine

    Intervention: High-dose influenza vaccine (Efluelda®) Dose: 0.7 mL intramuscular injection, single dose

    Biological: High-Dose Influenza Vaccine

Interventions

  • BiologicalStandard-Dose Influenza Vaccine

    0.5 mL intramuscular injection, single dose

  • 0.5 mL intramuscular injection, single dose

  • BiologicalHigh-Dose Influenza Vaccine

    0.7 mL intramuscular injection, single dose

06

What researchers measure

Primary outcomes

  1. Seroconversion Rate

    ≥4-fold increase in hemagglutination inhibition (HI) antibody titers

    Time frame: 4 weeks post-vaccination

Secondary outcomes

  1. Geometric Mean Titers

    Geometric Mean Titers (GMTs) of HI antibodies

    Time frame: Baseline, Day 7, Week 4, Month 6

  2. Cellular Immune Responses

    ELISpot (IFN-γ), activated T-cell frequency (CD38, HLA-DR)

    Time frame: Baseline, Day 7, Week 4

  3. B Cell Responses

    HA-specific B cell frequencies (A/H1N1, A/H3N2, B strains)

    Time frame: Baseline, Day 7, Week 4

  4. Microbiome Diversity and Composition

    Alpha diversity (Shannon index) Beta diversity (PERMANOVA)

    Time frame: Baseline and Week 4

  5. Microbiome Biomarker Identification

    Taxonomic and functional markers using LEfSe analysis

    Time frame: Baseline, Week 4

  6. Durability of Immune Response

    Antibody decay rate (half-life analysis)

    Time frame: Baseline, Week 4, Month 6

  7. Safety Outcomes

    Solicited adverse events (within 7 days) Unsolicited adverse events (within 30 days)

    Time frame: Day 7, Day 30

07

Study locations

1 site
  • Korea University Guro Hospital
    Seoul, Seoul 08308, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in this study, after de-identification, will be made available to researchers upon reasonable request. Access will be granted following review and approval by the study investigators and institutional review board, in accordance with applicable regulations and data sharing policies.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be available beginning 6 months following publication of the primary results and will remain available for 5 years.

Access criteria: Access to de-identified individual participant data and supporting documents will be provided to qualified researchers with a scientifically sound proposal. Requests will be reviewed and approved by the study investigators and the institutional review board. Data will be shared under a data use agreement to ensure participant confidentiality and compliance with applicable regulations.

Data sharing details ↗ · irb.kumc.or.kr

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jan 2026, 3 months.

Of 101 non-industry phase 4 interventional studies under Influenza, Human, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 52. This study's 3 months is below that.

Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartActual
Oct 25, 2025
Primary completionActual
Jan 31, 2026
CompletionActual
Aug 31, 2026
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07805837
Lead sponsor
Korea University Guro Hospital
Responsible party
Joon Young Song (Professor, Korea University Guro Hospital) — Principal investigator
First posted
Sep 4, 2026
Start date
Oct 25, 2025
Primary completion
Jan 31, 2026
Completion
Aug 31, 2026
Last update
Sep 4, 2026

Study contacts

Joon Young Song, MD, PhD
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MF59

Start the discussion